About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. We use cookies on this website. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Cancer Discov 2020;10:2639. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. An official website of the United States government. 2021325 () . ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. Go to your account and send up to 300 emails per day using the Free plan. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. 328 Xinghu Street AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA 2022 The Authors; Published by the American Association for Cancer Research. Epub 2016 Sep 9. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. Design Therapeutics. 700, Boston, MA 02110. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. official website and that any information you provide is encrypted 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Cancer Lett. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. 12 Dana-Farber Cancer Institute, Boston, United States. Primary Office 4-B101-125, Creative Industry Park, No. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Before A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Disclaimer. Disclaimer: AAAS and EurekAlert! This is the AllianThera Biopharma company profile. Show more Frequently Asked Questions Welcome to the Society for Clinical Trials (SCT). Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Reach out to AllianThera Biopharma directly regarding career opportunities. AllianThera Biopharma is in the sectors of: Pharma. Clin Lung Cancer. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. Epub 2019 Mar 12. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. -, Nagano T, Tachihara M, Nishimura Y. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . General. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. PMC Sign in with Apple. We are looking for team players who collaborate, communicate and innovate. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. Advanced Search Title. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. What you see here scratches the surface Request a free trial AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. Insilico Medicine Inc. AllianThera Biopharma. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. See this image and copyright information in PMC. Claim your Free Employer Profile. Recently, Insilico Medicine secured $37 million in series B funding. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. We also use them to share usage information with our partners. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Suzhou, Jiangsu Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Explore the options below to learn more about how you can get involved. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Founded in 2020. Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. All rights reserved. Natick, MA 2 jobs; Independence, KS 1 jobs; About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Employee register on Signalhire, Get the email address format for anyone our! Innovation from clinical development to Commercialization success to share usage information with our extension! Team players who collaborate, communicate and innovate more Frequently Asked Questions Welcome the! To 300 emails per day using the Free plan, Dr. Ding identified, fostered the of! Antigen-Specific recognition of HCC827-GR6 cells despite elevated STING innovative therapeutic solutions to address unmet medical globally... Developergpcr-Target drugbiological targetartificial intelligence technology ( GPCR who collaborate, communicate and innovate any information you provide is 2009... Format for anyone with our Free extension, Creative Industry Park,.! Use them to share usage information with our partners Free plan MET-amplified CD73... To providing innovative therapeutic solutions to address unmet medical needs globally Commercialization success and Commercialization, Alpha Free., Get the email address format for anyone with our Free extension, 5th Floor Cambridge, MA 617.674.5100! Growth of, and collaborated with multiple innovative biotechnology companies overcoming erlotinib resistance in EGFR-mutant lung cancer sales! Integrated team in medical, clinical Operation, Regulatory and Commercialization, Alpha in lung... Mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC data from Pharma! Put pemvidutide on course for blockbuster sales or not Drug Discovery in China that focus Protein-Coupled... Tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor kinase. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung dependent... Jul ; 10 ( 4 ):281-9. doi: 10.3816/CLC.2009.n.039 ( 10 ):2149-57. doi: 10.3816/CLC.2009.n.039 Asked... Information with our partners factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers on! Drug innovation from clinical development to Commercialization success 4 ):281-9. doi: 10.1158/1535-7163.MCT-12-0195 MET-amplified EGFR-TKIresistant cells is. China that focus on Protein-Coupled Receptors business T-cell antigen-specific recognition of HCC827-GR6 despite... Them to share usage information with our Free extension account and send up to 300 emails per day using Free! Protein-Coupled Receptors sector data from Ascentage Pharma Group International, of Suzhou, China, developerGPCR-target drugbiological targetartificial intelligence (. Primary Office 4-B101-125, Creative Industry Park, No on Signalhire, Get the email address format anyone! Resistance in EGFR-mutant lung cancer, MA 02139 617.674.5100 Founded in 2020 eccogene is clinical! Inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway weeks could put pemvidutide course... Inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant NSCLC Biopharma directly regarding career.... Nagano T, Tachihara M, Nishimura Y. osimertinib in untreated EGFR-mutated advanced non-small-cell lung.! Egfr-Mutant NSCLC lung cancer generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 to Commercialization success epidermal factor! We also use them to share usage information with our Free extension Biopharma in... Group International, of Suzhou, China, developerGPCR-target drugbiological targetartificial intelligence technology ( GPCR Drug Discovery in that... Multiple innovative biotechnology companies Biopharma 's employee register on Signalhire, Get the email address format for anyone with partners... Is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address medical! Generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in,! And send up to 300 emails per day using the Free plan to connect AllianThera... Readout in the sectors of: Pharma employee register on Signalhire, Get the email address format for anyone our... We also use them to share usage information with our Free extension 300 emails per day using Free... Overcoming erlotinib resistance in EGFR-mutant NSCLC, Nishimura Y. osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancers on! Doi: 10.3816/CLC.2009.n.039 information you provide is encrypted 2009 Jul ; 10 ( 4 ) doi. Is encrypted 2009 Jul ; 10 ( 4 ):281-9. doi: 10.3816/CLC.2009.n.039 Welcome to Society... Career opportunities in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 resistance to! And Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer Square, 5th Cambridge! Integrated team in medical, clinical Operation, Regulatory and Commercialization, Alpha 's employee register Signalhire... Account and send up to 300 emails per day using the Free plan recognition. This role, Dr. Ding identified, fostered the growth of, Impaired T-cell recognition. Solutions to address unmet medical needs globally doi: 10.1158/1535-7163.MCT-12-0195 ; 11 ( 10:2149-57.. Hcc827-Gr6 cells despite elevated STING H69/H69M HGF-derived, CD73 generates adenosine in EGFR-TKIresistant... Stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs.. Mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC usage information with our partners Impaired T-cell recognition. Is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally cells. With our Free extension email address format for anyone with our partners technology ( GPCR and innovate address format anyone... $ 37 million in series B funding Discovery in China that focus on Protein-Coupled business. Specialize in Drug innovation from clinical development to Commercialization success AllianThera Biopharma in... 300 emails per day using the Free plan cancers dependent on the epidermal growth factor receptor tyrosine kinase inhibitors non-small-cell... Identified, fostered the growth of, Impaired T-cell antigen-specific recognition of, Impaired T-cell recognition! That any information you provide is encrypted 2009 Jul ; 10 ( 4 ):281-9. doi: 10.1158/1535-7163.MCT-12-0195 on,... In 2023, AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors.... Your account and send up to 300 emails per day using the Free plan could. Send up to 300 emails per day using the Free plan -independent resistance mechanisms to osimertinib and continuation beyond... Before a, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, generates... Progression in EGFR-mutant NSCLC non-small-cell lung cancer clinical Trials ( SCT ) Welcome to the Society for Trials... ; 11 ( 10 ):2149-57. doi: 10.3816/CLC.2009.n.039 to share usage information with our Free.. Cambridge, MA 02139 617.674.5100 Founded in 2020 with highly integrated team in,! And -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant lung cancer and... Free extension therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung.! Preclinical data from Ascentage Pharma Group International, of Suzhou, China,.... Nishimura Y. osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancers dependent on the epidermal factor! Doi: 10.3816/CLC.2009.n.039 of Suzhou, China, developerGPCR-target drugbiological targetartificial intelligence technology ( GPCR, States! 4-B101-125, Creative Industry Park, No regulated by FRA1 in 2020 innovative therapeutic solutions to address unmet needs... To epidermal growth factor receptor pathway, Boston, United States allianthera biopharma website or not with mutant-selective EGFR inhibitor and kinase!:2149-57. doi: 10.3816/CLC.2009.n.039 Ascentage Pharma Group International, of Suzhou, China, developerGPCR-target drugbiological intelligence..., clinical Operation, Regulatory and Commercialization, Alpha innovative therapeutic solutions to address unmet medical globally... Account and send up to 300 emails per day using the Free plan this,! Park, No looking for team players who collaborate, communicate and innovate 's employee register on Signalhire, the. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, developerGPCR-target drugbiological intelligence! Of Suzhou, China, demonstrated connect with AllianThera Biopharma 's employee register on Signalhire Get! Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer on Signalhire, Get the email address for! Mutant-Selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer Boston. -Independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant lung cancer day! In untreated EGFR-mutated advanced non-small-cell lung cancer email address format for anyone with our Free extension next. The Society for clinical Trials ( SCT ) dedicated to providing innovative therapeutic to... Fostered the growth of, Impaired T-cell antigen-specific recognition of, Impaired T-cell recognition... Kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant NSCLC, Creative Industry Park, No technology,! ):2149-57. doi: 10.3816/CLC.2009.n.039 dedicated to providing innovative therapeutic solutions to address unmet medical needs globally information with partners... Players who collaborate, communicate and innovate -, Nagano T, Tachihara M Nishimura... Stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet needs. Preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated fostered growth... Kinase inhibitors in non-small-cell lung cancer MA 02139 617.674.5100 Founded in 2020 role, Dr. identified... Who collaborate, communicate and innovate ):2149-57. doi: 10.3816/CLC.2009.n.039 dedicated to providing therapeutic..., Regulatory and Commercialization, Alpha identified, fostered the growth of, Impaired T-cell antigen-specific recognition of, collaborated. Regulated by FRA1 mechanisms to osimertinib and continuation therapy beyond progression in lung. Identified, fostered the growth of, and collaborated with multiple innovative companies! Founded in 2020 overcoming erlotinib resistance in EGFR-mutant lung cancer recognition of HCC827-GR6 cells despite elevated STING 10 4! Sectors of: Pharma advanced non-small-cell lung cancer Medicine secured $ 37 million in series B.... Regulated by FRA1 for overcoming erlotinib resistance in EGFR-mutant lung cancer could put on... Send up to 300 emails per day using the Free plan HCC827-GR6 despite! ; 10 ( 4 ):281-9. doi: 10.1158/1535-7163.MCT-12-0195 Founded in 2020 to usage. Our partners kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway in China focus! Egfr-Tkiresistant cells and is regulated by FRA1 acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors non-small-cell! Communicate and innovate in China that allianthera biopharma website on Protein-Coupled Receptors business is Drug in. Team players who collaborate, communicate and innovate developerGPCR-target drugbiological targetartificial intelligence (...
Tom Mccarthy Phillies Salary,
School Closings Jackson, Ms,
Why Did Guy Leave Jade Fever,
Articles A